Metolazone and Traumatic intracranial haemorrhage - a phase IV clinical study of FDA data

Summary:

Traumatic intracranial haemorrhage is reported only by a few people who take Metolazone.

The phase IV clinical study analyzes which people take Metolazone and have Traumatic intracranial haemorrhage. It is created by eHealthMe based on reports of 12,195 people who have side effects while taking Metolazone from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

12,195 people reported to have side effects when taking Metolazone.
Among them, 2 people (0.02%) have Traumatic intracranial haemorrhage.

What is Metolazone?

Metolazone has active ingredients of metolazone. It is often used in swelling. eHealthMe is studying from 12,267 Metolazone users for its effectiveness, alternative drugs and more.

What is Traumatic intracranial haemorrhage?

Traumatic intracranial haemorrhage (a bleeding in brain due to trauma) is found to be associated with 309 drugs and 181 conditions by eHealthMe.

Number of Metolazone and Traumatic intracranial haemorrhage reports submitted per year:

Could Metolazone cause Traumatic intracranial haemorrhage?

Time on Metolazone when people have Traumatic intracranial haemorrhage *:

Gender of people who have Traumatic intracranial haemorrhage when taking Metolazone *:

female: 50 %
male: 50 %

Age of people who have Traumatic intracranial haemorrhage when taking Metolazone *:

Common drugs people take besides Metolazone *:

Haldol: 2 people, 100.00%
Aldactone: 2 people, 100.00%

Common side effects people have besides Traumatic intracranial haemorrhage *:

Skull Fractured Base: 2 people, 100.00%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 2 people, 100.00%
Fall: 2 people, 100.00%
Dehydration (dryness resulting from the removal of water): 2 people, 100.00%
Acute Kidney Failure: 2 people, 100.00%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 50.00%
Fainting (loss of consciousness and postural tone): 1 person, 50.00%
Delirium Tremens (a psychotic condition typical of withdrawal in chronic alcoholics): 1 person, 50.00%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 50.00%
Blood Creatinine Increased: 1 person, 50.00%

Common conditions people have *:

Psychotic Disorder: 2 people, 100.00%
Hypertensive Heart Disease: 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Metolazone and have Traumatic intracranial haemorrhage?

Check whether Traumatic intracranial haemorrhage is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Traumatic intracranial haemorrhage and when was it recovered:

Traumatic intracranial haemorrhage in Metolazone

Expand to all the drugs that have ingredients of metolazone:

Traumatic intracranial haemorrhage and drugs with ingredients of metolazone

Alternative drugs to, pros and cons of Metolazone:

Metolazone (12,267 reports)

Common Metolazone side effects:

Browse all side effects of Metolazone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Traumatic intracranial haemorrhage treatments and more:

Traumatic intracranial haemorrhage (816 reports)

COVID vaccines that are related to Traumatic intracranial haemorrhage:

Common drugs associated with Traumatic intracranial haemorrhage:

Xarelto: 105 reports

How the study uses the data?

The study uses data from the FDA. It is based on metolazone (the active ingredients of Metolazone) and Metolazone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.